Liquid Phase Peptide Synthesis Market size is poised to reach USD 15 Billion by the end of 2036, growing at a CAGR of 10% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of liquid phase peptide synthesis was over USD 5 Billion. Growing Demand for peptide-based therapeutics due to their effectiveness in treating various diseases like cancer, metabolic disorders, and hormonal deficiencies fuels the LPPS market. Cancer is one of the leading causes of death globally, Current cancer treatment regimens often cause significant adverse side effects and fall short of effectively eliminating advanced disease. Because of the diverse functions that peptides offer, this nonviral carrier has rapidly gained exposure and popularity as a prospective delivery vehicle. In 2020, there were about 18.1 million cases of cancer worldwide.
Moreover, liquid-phase synthesis was the original method for creating peptides, numerous studies have looked into how to improve solid-phase synthesis in order to decrease costs, increase scalability, and waste less amino acids and solvents. High-volume industrial production uses liquid-phase peptide synthesis, which can produce higher-quality peptides at a cost of more time.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
~ 10% |
|
Base Year Market Size (2023) |
~ USD 5 Billion |
|
Forecast Year Market Size (2036) |
~ USD 15 Billion |
|
Regional Scope |
|
End-User (Pharmaceutical & Biotechnology Industry, Contract Development & Manufacturing organizations, Academic & Research Institutes)
Pharmaceutical & biotechnology industry segment is anticipated to hold 45% share of the global liquid phase peptide synthesis market during the forecast period. This is owing to the extensive use of peptides in drug development and manufacturing. For instance, since 2000, 33 non-insulin peptide medications have received approvals across the globe. Furthermore, these peptide medications are no longer just natural amino acid compositions or hormone mimics. For example, ziconotide14,15 is a neurotoxic peptide derived from the cone snail Conus magus, which was approved in 2004 and is used to manage severe chronic pain; teduglutide is a glucagon-like peptide 2 (GLP-2) analog used to treat short bowel syndrome; and enfuvirtide is a 36-amino acid biomimetic peptide mimicking human immunodeficiency virus (HIV) proteins used in combination therapy for the treatment of HIV-112,13.
Application (Therapeutics, Diagnostics, Research Purposes, cosmetics, Food)
The therapeutics segment in the liquid phase peptide synthesis market is estimated to hold a major revenue share by 2036. due to the increasing demand for peptide-based drugs in various disease treatments. The pharmaceutical industry’s continual efforts to harness peptides for targeted therapies and the development of biologics further bolster this segment’s dominance in the market. According to Research Nester Analysts' analysis, the proportion of cancer patients in the United States who qualify for and benefit from genome-targeted therapy has grown over time, rising from an estimated 2.7 in 2006 to 7% in 2020.
Our in-depth analysis of the global market includes the following segments:
|
End-User |
|
|
Application |
|
North American Market Forecast
North America liquid phase peptide synthesis market is estimated to account for 42% of the revenue share by 2036. The North American market stands as a prominent hub in the global landscape due to several key factors. Fueled by robust research and development activities, the region witnesses extensive utilization of peptides in drug discovery and development by pharmaceutical giants and biotechnology firms. In 2021, research and development expenditure in the United States pharmaceuticals industry amounted to around USD 102 billion. With a strong presence of cutting-edge technology and state-of-the-art infrastructure, North America showcases a significant market share in Liquid Phase Peptide Synthesis.
APAC Market Statistics
Asia Pacific region is also poised to garner significant revenue share, the Asia Pacific liquid phase peptide synthesis market is experiencing substantial growth attributed to several key factors. Rapid economic development, coupled with increasing healthcare expenditure across countries like China, India, Japan, South Korea, and others, is driving the market’s expansion. The region’s pharmaceutical industry is witnessing remarkable advancements, fostering a conducive environment for peptide synthesis technologies. Additionally, the escalating prevalence of chronic diseases and the growing demand for innovative therapeutic solutions fuel the adoption of liquid-phase peptide synthesis in drug discovery and development within the Asia Pacific.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?